资源分层指南——经典型霍奇金淋巴瘤。
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
机构信息
Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland.
Medical Oncology, CHIMOMO Department, University of Modena and Reggio Emilia, Via Università 4, 41121 Modena, Italy.
出版信息
Int J Environ Res Public Health. 2020 Mar 9;17(5):1783. doi: 10.3390/ijerph17051783.
Abstract
Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in settings with restricted healthcare resources. Considerable discrepancies in Hodgkin lymphoma patient survival exist, with poorer outcomes reported in resources-constrained settings. Resources-stratified guidelines for diagnosis, staging and treatment of Hodgkin lymphoma were derived in an effort to optimize patient outcome provided a given setting of available resources. These guidelines were derived based on the framework of the Breast Health Global Initiative stratifying resource levels in basic, core, advanced and maximal categories.
摘要
霍奇金淋巴瘤是一种主要影响年轻人的血液系统恶性肿瘤。按照目前的治疗标准，霍奇金淋巴瘤是一种高度可治愈的疾病。然而，最新的霍奇金淋巴瘤治疗指南暗示需要获得诊断和治疗方式，但在医疗资源有限的环境中可能无法获得这些方式。霍奇金淋巴瘤患者的生存存在相当大的差异，在资源有限的环境中报告的结果较差。为了在给定的可用资源环境中优化患者的治疗效果，制定了针对霍奇金淋巴瘤的诊断、分期和治疗的资源分层指南。这些指南是基于乳腺健康全球倡议的框架制定的，该框架将资源水平分为基础、核心、高级和最大类别。
相似文献
1
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.资源分层指南——经典型霍奇金淋巴瘤。
Int J Environ Res Public Health. 2020 Mar 9;17(5):1783. doi: 10.3390/ijerph17051783.
2
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines.亚洲 B 细胞非霍奇金淋巴瘤的管理：资源分层指南。
Lancet Oncol. 2013 Nov;14(12):e548-61. doi: 10.1016/S1470-2045(13)70450-9.
3
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.资源有限国家的乳腺癌：《2005年全球乳腺癌防治倡议》指南概述
Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15. doi: 10.1111/j.1075-122X.2006.00199.x.
4
[Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].青少年和青年的霍奇金淋巴瘤与非霍奇金淋巴瘤
Bull Cancer. 2016 Dec;103(12):1035-1049. doi: 10.1016/j.bulcan.2016.10.011. Epub 2016 Nov 17.
5
Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report.伪装成慢性复发性多灶性骨髓炎的经典型霍奇金淋巴瘤：一例报告
J Med Case Rep. 2017 Feb 18;11(1):45. doi: 10.1186/s13256-017-1224-4.
6
Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.美国晚期经典型霍奇金淋巴瘤的当代结果：监测、流行病学和最终结果数据库分析。
Oncologist. 2019 Nov;24(11):1488-1495. doi: 10.1634/theoncologist.2019-0172. Epub 2019 Aug 29.
7
Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma.老年霍奇金淋巴瘤患者的治疗强度与生存的关系。
JAMA Netw Open. 2021 Oct 1;4(10):e2128373. doi: 10.1001/jamanetworkopen.2021.28373.
8
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.反应适应放疗省略与巩固化疗在中晚期经典霍奇金淋巴瘤患儿和青少年中的比较（欧洲血液与骨髓移植学会-儿童肿瘤组 Hodgkin 淋巴瘤协作组 1 期临床试验）：一项带有开放性标签、嵌入式、多国、非劣效、随机对照滴定研究。
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9.
9
ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.ACR 适宜性标准：儿科霍奇金淋巴瘤。
Pediatr Blood Cancer. 2014 Jul;61(7):1305-12. doi: 10.1002/pbc.24983. Epub 2014 Feb 24.
10
[National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma].[非霍奇金淋巴瘤诊断与治疗国家指南]
Rev Invest Clin. 2013 Jun;65 Suppl 2:s5-27.
引用本文的文献
1
Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access.在无法获得丙卡巴肼的泰国经典型霍奇金淋巴瘤患者中，ABVD方案的治疗结果
Sci Rep. 2025 Jul 1;15(1):22211. doi: 10.1038/s41598-025-07187-z.
2
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective.在晚期经典型霍奇金淋巴瘤中应用正电子发射断层扫描-计算机断层扫描和报告的 Deauville 评分的真实世界研究：社区肿瘤学实践的观点。
JCO Oncol Pract. 2023 Oct;19(10):860-870. doi: 10.1200/OP.23.00021. Epub 2023 Aug 31.
3
Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study.在资源有限的国家，接受 ABVD 与递增 BEACOPP 方案治疗的成人霍奇金淋巴瘤患者的生存率：一项观察性研究。
Cancer Rep (Hoboken). 2023 Aug;6(8):e1839. doi: 10.1002/cnr2.1839. Epub 2023 May 31.
4
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study.肿瘤学家对经典霍奇金淋巴瘤中采用中期正电子发射断层扫描（PET）指导适应性治疗方案选择的观察：真实世界 CONNECT 研究。
JCO Oncol Pract. 2023 Jun;19(6):e867-e876. doi: 10.1200/OP.22.00811. Epub 2023 Mar 22.
5
A multidimensional framework for rating health system performance and sustainability: A nine plus one ranking system.多维框架评估卫生系统绩效和可持续性：九加一排名系统。
J Glob Health. 2021 May 8;11:04025. doi: 10.7189/jogh.11.04025.
6
Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma.非霍奇金淋巴瘤中的霍奇金里德-斯腾伯格样细胞
Diagnostics (Basel). 2020 Nov 27;10(12):1019. doi: 10.3390/diagnostics10121019.
本文引用的文献
1
Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study.全球、区域和国家霍奇金淋巴瘤负担：2017 年全球疾病负担研究估计。
J Hematol Oncol. 2019 Oct 22;12(1):107. doi: 10.1186/s13045-019-0799-1.
2
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.PET 指导下治疗新诊断的晚期霍奇金淋巴瘤（AHL2011）：一项随机、多中心、非劣效性、3 期研究。
Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.
3
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.适应性治疗后晚期霍奇金淋巴瘤患者卵巢功能的决定因素（RATHL）：一项随机 3 期试验的二次分析。
Lancet Oncol. 2018 Oct;19(10):1328-1337. doi: 10.1016/S1470-2045(18)30500-X. Epub 2018 Sep 13.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.CALGB 50604：基于中期 PET 的非大肿块早期霍奇金淋巴瘤风险适应性治疗。
Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.
6
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.霍奇金淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
7
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.NCCN 指南解读：霍奇金淋巴瘤，第 1.2018 版。
J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.
8
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.本妥昔单抗联合化疗治疗Ⅲ期或Ⅳ期霍奇金淋巴瘤
N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10.
9
High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.霍奇金淋巴瘤的原发性难治性疾病发生率高且无进展生存率低：拉丁美洲一个中心的十年经验
Rev Bras Hematol Hemoter. 2017 Oct-Dec;39(4):325-330. doi: 10.1016/j.bjhh.2017.08.001. Epub 2017 Sep 14.
10
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.PET 引导治疗晚期霍奇金淋巴瘤（HD18）：德国霍奇金研究组开展的一项开放标签、国际、随机 3 期临床试验的最终结果。
Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.
Zotero 插件